{"meshTagsMajor":["Mutation"],"meshTags":["Neurofibromin 1","Precision Medicine","Humans","Melanoma","Mutation"],"meshMinor":["Neurofibromin 1","Precision Medicine","Humans","Melanoma"],"genes":["NF1","BRAF","NRAS","RAS","MAP kinase","RAS"],"publicationTypes":["News"],"abstract":"Whole-exome sequencing of 213 tumor samples shows that NF1 is mutated in 13.1% of melanomas. The gene is usually mutated in tumors that don\u0027t carry mutations in BRAF or NRAS, and it may be a cancer driver. However, loss of the gene didn\u0027t predict whether RAS activity increased or whether cell lines responded to inhibitors of the MAP kinase pathway, which RAS activates. ","title":"NF1 Mutations Prevalent but Not Clinically Relevant.","pubmedId":"26283687"}